Interfering with Tumor Hypoxia for Radiotherapy Optimization

Telarovic, Irma; Wenger, Roland H.; Pruschy, Martin

doi:10.1186/s13046-021-02000-x

Cited by 98 publications

(72 citation statements)

References 352 publications

(327 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oxygen deficiency is present in the majority of solid human tumors, due to inadequate and heterogeneous vascular network. For this reason, strategies to overcome hypoxia-induced radioresistance are of clinical importance [83,84].…”

Section: Hypoxic Cell Radiosensitizersmentioning

confidence: 99%

Combining Nanocarrier-Assisted Delivery of Molecules and Radiotherapy

Gomes

Franco²

2022

Pharmaceutics

View full text Add to dashboard Cite

Cancer is responsible for a significant proportion of death all over the world. Therefore, strategies to improve its treatment are highly desired. The use of nanocarriers to deliver anticancer treatments has been extensively investigated and improved since the approval of the first liposomal formulation for cancer treatment in 1995. Radiotherapy (RT) is present in the disease management strategy of around 50% of cancer patients. In the present review, we bring the state-of-the-art information on the combination of nanocarrier-assisted delivery of molecules and RT. We start with formulations designed to encapsulate single or multiple molecules that, once delivered to the tumor site, act directly on the cells to improve the effects of RT. Then, we describe formulations designed to modulate the tumor microenvironment by delivering oxygen or to boost the abscopal effect. Finally, we present how RT can be employed to trigger molecule delivery from nanocarriers or to modulate the EPR effect.

show abstract

Section: Hypoxic Cell Radiosensitizersmentioning

confidence: 99%

Combining Nanocarrier-Assisted Delivery of Molecules and Radiotherapy

Gomes

Franco²

2022

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Hypoxia is defined as oxygen insufficiency in cells, and it can be used as a prognostic indicator. Hypoxia has shown particular utility in therapeutic cancer management, including responses to chemotherapy or radiation therapy [ 33 , 34 , 35 , 36 ]. Another noteworthy aspect of hypoxia is the prediction of metastases in tumor cells which are related to hypoxia’s role in deoxyribonucleic acid (DNA) mutations and malignant, atypical cells [ 10 ].…”

Section: Cervical Cancermentioning

confidence: 99%

A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies

Vahidfar

Farzanefar

Ahmadzadehfar

et al. 2022

Cancers

View full text Add to dashboard Cite

Nuclear medicine is defined as the diagnosis and the treatment of disease using radiolabeled compounds known as radiopharmaceuticals. Single-photon emission computed tomography/computed tomography (SPECT/CT) and positron emission tomography/computer tomography (PET/CT) based radiopharmaceuticals have proven reliable in diagnostic imaging in nuclear medicine and cancer treatment. One of the most critical cancers that also relies on an early diagnosis is gynecological cancer. Given that approximately 25% of all cancers in developing countries are a subset of gynecological cancer, investigating this cancer subtype is of significant clinical worth, particularly in light of its high rate of mortality. With accurate identification of high grade distant abdominal endometrial cancer as well as extra abdominal metastases, 18F-Fluorodeoxyglucose ([18F]FDG) PET/CT imaging is considered a valuable step forward in the investigation of gynecological cancer. Considering these factors, [18F]FDG PET/CT imaging can assist in making management of patient therapy more feasible. In this literature review, we will provide a short overview of the role of nuclear medicine in the diagnosis of obstetric and gynecological cancers.

show abstract

“…The PPP, whose initial metabolite glucose-6-phosphate, is supplied via glycolysis, generates pentose sugars and ribose-5-phosphate and generates NADPH as a byproduct (Patra et al, 2014). Because NADPH is a coenzyme of an antioxidant enzyme glutathione reductase, which converts oxidized glutathione (GSSG) into reduced form (GSH), and ribose-5-phosphate is essential for nucleotide synthesis, so HIF-1-mediated activation of the PPP is associated with the radioresistance of hypoxic cancer cells (Harada, 2016;Nakashima et al, 2017;Telarovic et al, 2021).…”

Section: Tumor Metabolism Alterations In Irradiated Cellsmentioning

confidence: 99%

Molecular Mechanisms Underlying Cancer Cell Radioresistance

Chorna

2022

SJPU

View full text Add to dashboard Cite

Radioresistance of the tumor cells remains a significant obstacle for the radiotherapy treatment of cancer. Radioresistance involves multiple genes, factors, and mechanisms that adapt cancer cells or tissues to radiotherapy-induced changes and develop resistance to ionizing radiation. The major studies of the effect of radiation on cells reported include the following areas: 1) the study of DNA damages and their repair; 2) mutations in tumor suppressor genes and radiation-induced oncogene expression; 3) the role of growth factors and cytokines; 4) violation of the cell cycle; 5) elucidation of the mechanisms of apoptosis and necrosis. This review aimed to provide a theoretical basis, which may improve the sensitivity of cancer cells to radiotherapy. It focuses on the roles of tumor metabolism, DNA repair capacity, cell cycle checkpoints, and the tumor microenvironment in the development of radioresistance of cancer cells. Understanding the molecular alterations that lead to radioresistance may provide new diagnostic markers and therapeutic targets to improve radiotherapy efficacy.

show abstract

Interfering with Tumor Hypoxia for Radiotherapy Optimization

Cited by 98 publications

References 352 publications

Combining Nanocarrier-Assisted Delivery of Molecules and Radiotherapy

Combining Nanocarrier-Assisted Delivery of Molecules and Radiotherapy

A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies

Molecular Mechanisms Underlying Cancer Cell Radioresistance

Contact Info

Product

Resources

About